Clinical trials: Colorectal Cancer, Metastatic
First Line WT KRAS mCRC
PREMIUM, Observational Study
PREMIUM is an observational pharmaco-epidemiologic, transversal, multi-centric, prospective cohort study and with independent investigators.
- Trial name
- NCT01756625
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Dr.Laurent Mineur
Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Advanced Therapies for Liver Metastases
Liver metastases (MTS) are the main cause of death for patients affected by colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC), thus representing the major unmet clinical need for these malignancies.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Liver Metastasis, IPMN, Pancreatic
- Trial name
- LiMeT (NCT04622423)
- Where
- Italy
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Colorectal Cancer, Advanced Cancer
Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type
Recent preclinical studies suggest that combining MEK and MDM2 inhibition synergize to induce apoptosis in RAS/BRAF-mutant and TP53 wild-type CRC models.
- Conditions
- Colorectal Cancer, Advanced Cancer, Metastatic Cancer
- Trial name
- TRAHD (NCT03714958)
- Testing
- HDM201, Trametinib
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Centre Leon Berard
Metastatic Colorectal Cancer
SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
This is an open label, single-arm, multi-center, phase II study of SHR-1210 in metastatic colorectal cancer patients with the recurrent lesion(s) post-surgery or the untreated mCRC.
- Trial name
- NCT03645876
- Testing
- SHR-1210, BP102, oxaliplatin
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Colorectal Cancer, RAS Mutation
Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer
A phase II clinical study of Sintilimab (IBI308) combined with Bevacizumab, Oxaliplatin and Capecitabine regimen as first-line treatment in patients with RAS-mutant and microsatellite stable metastatic colorectal cancer.
- Conditions
- Metastatic Colorectal Cancer, RAS Mutation, Microsatellite Stable
- Trial name
- NCT04194359
- Testing
- Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colorectal Cancer
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00423696
- Testing
- bevacizumab, capecitabine, fluorouracil
- Where
- 15 sites in France
- Volunteers
- 145 people
- Sponsor
- UNICANCER
Colorectal Cancer
Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether fluorouracil and leucovorin plus irinotecan is more effective than fluorouracil…
- Trial name
- NCT00004885
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- 57 sites in Austria, Belgium and 7 more
- Volunteers
- 430 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastatic Colorectal Cancer
A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) of rivoceranib when used in combination with trifluridine/tipiracil in participants with mCRC and to assess progression-free survival (PFS) in…
- Trial name
- NCT04073615
- Testing
- Rivoceranib, Trifluridine/Tipiracil
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Elevar Therapeutics
Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic
MGD019 DART® Protein in Unresectable/Metastatic Cancer
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab.
- Conditions
- Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer
- Trial name
- NCT03761017
- Testing
- Lorigerlimab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 162 people
- Sponsor
- MacroGenics
Colorectal Cancer Metastatic, Liver Metastases
Chemotherapy and Tumor Clearance in Hepatic Resections for Colorectal Liver Metastases.
Retrospective analysis of a prospectively collected database of 170 patients between 2004 and 2020, who underwent liver resections for CRLM (colorectal liver metastases) at The Queen Elizabeth Hospital trying to determine rates…
- Trial name
- NCT05273489
- Testing
- Hepatectomy
- Volunteers
- 170 people
- Sponsor
- Hospital Maciel
Colorectal Cancer
Cetuximab Monotherapy Maintenance Treatment in mCRC
Investigating the efficacy of Cetuximab Monotherapy versus Continuation after induction treatment with chemotherapy + Cetuximab in inoperable or irresectable and non-progressive metastatic colorectal cancer after first line…
- Trial name
- NCT02978313
- Testing
- Cetuximab, mFOLFOX6, FOLFIRI
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Metastatic Colorectal Cancer, Metastatic Cervical Cancer
Safety of Effivia®, a Bevacizumab Biosimilar
This is a post-marketing observational study aimed to evaluated the safety profile of Effivia®, a biosimilar of bevacizumab, in mexican patients with different types of cancer.
- Conditions
- Metastatic Colorectal Cancer, Metastatic Cervical Cancer, Non Squamous Non Small Cell Lung Cancer
- Trial name
- NCT06313268
- Testing
- Bevacizumab Biosimilar MB02
- Where
- 5 sites in Mexico
- Volunteers
- 83 people
- Sponsor
- Laboratorios Liomont
Metastatic Colorectal Cancer
Sacituzumab Govitecan in Metastatic Colorectal Cancer
This is a Phase: II/III, open-label, multicenter (at least four centers in Germany) study of Sacituzumab Govitecan (SG) in metastatic colorectal cancer patients who are refractory to at least two lines of standard of care…
- Trial name
- TROPHIT1 (NCT06243393)
- Testing
- Sacituzumab Govitecan (SG), Physicians Choice (PhC).
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- University Hospital Heidelberg
Colorectal Cancer Metastatic, Squamous Cell Carcinoma of Head and Neck
A Phase 1b Study of WU-NK-101 in Combination With Cetuximab
This study is a Phase 1b open-label study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of WU-NK-101 in combination with cetuximab in patients with advanced and/or metastatic CRC (Cohort…
- Trial name
- NCT05674526
- Testing
- WU-NK-101 - Dose Escalation, Cetuximab - Dose Escalation, WU-NK-101 - Cohort Expansion
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Allotera Therapeutics
Colorectal Cancer
Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006468
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Metastatic Colorectal Cancer
The Gene Profiles of Primary and Heterogeneous Metastases of Colorectal Cancer
The incidence and mortality of colorectal cancer in China's cancer disease spectrum is on the rise, and it is a common malignant tumor that harms the health of Chinese residents.In patients with synchronous metastatic colorectal…
- Trial name
- NCT04230018
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Solid Tumor, Breast Cancer
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerability, PK, and PD of SON-DP in participants with relapsed/refractory/intolerant…
- Conditions
- Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT05989724
- Testing
- SON-DP
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- Qurgen Inc.
Liver Metastases From Colorectal Primary Cancer
Ultrasound Liver Intraoperative Imaging With SonoVue®
Hypothesis: Use of contrast ultrasound showed interesting results, which can increase ultrasonography sensitivity performed during surgery in the evaluation of operable liver metastases.
- Trial name
- ULIIS (NCT01880554)
- Testing
- Contrast-enhanced intraoperative ultrasound
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Institut Bergonié
Colorectal Adenocarcinoma Metastatic to the Liver
Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM
To date no prospective trials have been completed that demonstrated whether HAI is an effective adjunct to systemic chemotherapy (target therapy) with respect to advantages in conversional resection rates and survival compared…
- Trial name
- NCT03125161
- Testing
- HAI, chemotherapy ± target therapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Fudan University